Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.
Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy. On the therapeutic side, the company is advancing radioligand therapies aimed at delivering targeted radiation to tumors while sparing healthy tissue. These programs are supported by a framework of Good Manufacturing Practice (GMP) production facilities, enabling scale-up for both clinical trials and commercial supply.
Headquartered in Melbourne, Australia, Telix operates across multiple geographies with strategic commercial and clinical development hubs in North America and Europe. The company maintains a global network of research collaborations, clinical trial sites and distribution partners to support regulatory filings and market access. Telix also invests in in-house radiochemistry and formulation capabilities to ensure consistent quality of its radiopharmaceutical products.
Founded in 2015 as a spin-out from a radiopharmaceutical research group, Telix has since assembled a leadership team with deep expertise in nuclear medicine, oncology and drug development. Under the guidance of its executive leadership, the company continues to advance its clinical pipeline and prepare for product launches, with the goal of transforming patient care through targeted imaging and therapy solutions.
AI Generated. May Contain Errors.
